Author:
Ibrahim Ibrahim F.,Rice Lawrence
Publisher
Springer International Publishing
Reference69 articles.
1. Beauregard KM, Carper K. Outpatient prescription anticoagulants utilization and expenditures for the U.S. Civilian noninstitutionalized population age 18 and older. Statistical Brief #268. Rockville, MD: Agency for Healthcare Research and Quality; 2007 (Government agency report).
2. Eickelboom JW, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319–30.
3. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AG, Hasselblad V, Ortel TL, BRIDGE Investigators. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373:823–33.
4. Matsumoto M, Mabe K, Tsuda M, Ono M, Omori S, Takahashi M, Yoshida T, Ono S, Nakagawa M, Nakagawa S, Shimizu Y, Kudo T, Sakamoto N, Kato M. Multicenter study on hemorrhagic risk of heparin bridging therapy for periendoscopic thromboprophylaxis. BMC Gastroenterol. 2015;15:89.
5. Palmerini, et al. 3, 6 or 12 months of DAPT after DES with or without ACS. Eur Heart J. 2017;38:1034–43.